Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer

被引：0

作者：

Matsue, Kosei ^{[1
]}

Matsuo, Keitaro ^{[2
]}

Fujiwara, Hideaki ^{[1
]}

Iwama, Kan-ichi ^{[1
]}

Hayama, Brian Y. ^{[1
]}

Kimura, Shun-ichi ^{[1
]}

Yamakura, Masayuki ^{[1
]}

Takeuch, Masami ^{[1
]}

机构：

[1] Kameda Gen Hosp, Div Hematol Oncol, Dept Med, Kamogawa, Chiba 2968602, Japan

[2] Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi 464, Japan

来源：

THROMBOSIS AND HAEMOSTASIS | 2009年 / 101卷 / 06期

关键词：

CHRONIC MYELOID-LEUKEMIA; ALPHA-2-ANTIPLASMIN; THERAPY;

D O I：

10.1160/TH08-09-0614

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1170 / 1171

页数：2

共 14 条

[1]

Druker BJ., 2001, NEW ENGL J MED, V344, P10311037

[2] Congenital α2-plasmin inhibitor deficiencies:: a review [J].

Favier, R ;

Aoki, N ;

de Moerloose, P .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (01) :4-10

[3] Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment [J].

Goldman, JM ;

Melo, JV .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1451-1464

[4]

HERSCH SL, 1987, BLOOD, V69, P1315

[5]

KLUFT C, 1982, BLOOD, V59, P1169

[6] Tyrosine kinases as targets for cancer therapy [J].

Krause, DS ;

Van Etten, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :172-187

[7] Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study [J].

Larson, Richard A. ;

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Riviere, Gilles J. ;

Krahnke, Tillmann ;

Gathmann, Insa ;

Wang, Yanfeng .

BLOOD, 2008, 111 (08) :4022-4028

[8] Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia [J].

Legros, L ;

Bourcier, C ;

Jacquel, A ;

Mahon, FX ;

Cassuto, JP ;

Auberger, P ;

Pagès, G .

BLOOD, 2004, 104 (02) :495-501

[9] SELECTIVE DETERMINATION OF ALPHA-2-PLASMIN INHIBITOR ACTIVITY IN PLASMA USING CHROMOGENIC SUBSTRATE [J].

MATSUDA, T ;

OGAWARA, M ;

MIURA, R ;

SEKI, T ;

MATSUMOTO, T ;

TERAMURA, Y ;

NAKAMURA, K .

THROMBOSIS RESEARCH, 1984, 33 (04) :379-388

[10] α2-antiplasmin on cardiovascular diseases [J].

Matsuno, H .

CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (07) :841-847

← 1 2 →